Filing summary
Entity and period: The supplied filing is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, not a filing identified as Pavella Therapeutics, Inc. The company is a clinical-stage biopharmaceutical business developing Anticalin-based drug candidates. It reports in U.S. dollars, while its operating subsidiary’s functional currency is the euro.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $217,621 | $1,372,879 |
| Research and development expense | $1,524,631 | $1,222,745 |
| General and administrative expense | $2,394,323 | $821,351 |
| Operating loss | $3,701,333 | $671,217 |
| Net loss | $3,704,734 | $779,905 |
| Net loss per share, basic and diluted | $0.13 | $0.07 |
| Net cash used in operations | $3,720,571 | $418,477 |
- Revenue was from collaboration, research-service and grant sources, not product sales. Q1 2015 revenue was entirely grants ($218,000, rounded); no collaboration milestone revenue was recorded.
- Cash and cash equivalents were $13.17 million at March 31, down $5.31 million from year-end. The decline included operating cash use of $3.72 million, debt repayment of $1.00 million, investing cash use of $41,000 and a $546,000 adverse exchange-rate effect.
- Total assets were $16.77 million; total liabilities were $2.55 million; stockholders’ equity was $14.23 million. Current assets were $14.97 million and current liabilities $2.25 million. The TBG loan was repaid in full during the quarter; no bank loan remained at March 31.
- The company reported no product-sales base from which to assess product margins; gross margin is not presented as a meaningful standalone measure in the filing.
Changes versus the prior-year quarter
- Revenue fell by about $1.16 million, principally because collaboration projects had been handed over to partners in 2014, ending related upfront-payment recognition and research funding; no collaboration milestones were achieved in Q1 2015. Grant revenue increased, largely reflecting higher European Commission reimbursement for PRS-080.
- R&D expense rose about $302,000, with higher PRS-080 clinical-trial and 300-Series activity. G&A expense increased about $1.57 million, driven by public-company legal costs, stock-based compensation, consulting and business-development costs.
- Net loss widened by about $2.92 million. Weighted-average shares rose to 29.29 million from 11.83 million, reflecting the company’s December 2014 acquisition and financing history; the year-over-year comparison is therefore affected by a substantially changed corporate and share-capital structure.
Business outlook, risks and unusual items
- PRS-080 was in a Phase I trial in healthy volunteers, begun in November 2014; management expected to report data by year-end 2015. PRS-060 was in preclinical development, with a Phase I trial intended for 2016. The company also planned to select a 300-Series oncology candidate for possible clinical development by year-end 2015.
- Management expected substantial losses and increasing R&D costs for several years, and said it did not expect product revenue for at least the next several years. It stated existing cash was expected to fund operations and capital expenditure needs for at least the next 12 months, while also stating additional funding would be needed to continue operations and pursue its plans. Funding availability was uncertain; failure to raise capital could force program delays, reductions or rights transfers.
- A material contingency is the TUM arbitration over out-license fees tied to the company’s technology license. Pieris calculated approximately $0.4 million due for the disputed period; TUM asserted approximately $3.4 million, excluding VAT, and had threatened license termination. Pieris had recorded a $327,937 liability. The filing warned an adverse ruling could materially harm results and financial condition.
- Management reported disclosure controls and procedures were not effective at quarter-end because of a material weakness previously disclosed in the 2014 Form 10-K. It reported no material changes in internal control during the quarter.
- Other notable items: 150,000 shares were issued for investor-relations consulting, with 60,000 subject to potential forfeiture; the quarter included $217,335 of stock-based compensation. A sponsored research agreement with Stanford was signed May 14, 2015; its financial impact was still being evaluated.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing names Pieris Pharmaceuticals, Inc., whereas the request metadata names Pavella Therapeutics, Inc.
- Review the latest status and potential financial or licensing consequences of the TUM arbitration, including the recorded reserve versus TUM’s claim.
- Assess the cash-burn rate, collaboration funding outlook and need and availability of additional capital against the stated 12-month funding expectation.
- Track PRS-080 trial results and the timing and costs of PRS-060 and 300-Series development against management’s plans.
- Review remediation of the disclosed material weakness and the effects of equity issuance, stock compensation and potential dilution.